Izumiyama, K., Inao, T., Goto, H., Harada, S., Senjo, H., Suto, K., Hashiguchi, J., Ogasawara, R., Saga, T., Igarashi, T., Wakasa, K., Kasahara, I., Takeda, Y., Yamaguchi, K., Shigematsu, A., Takahata, M., Fujimoto, K., Haseyama, Y., Nagashima, T., Sakai, H., Kakinoki, Y., Kurosawa, M., Yokota, I. and Teshima, T. (2020) “Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2023.284841.